Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort
- 10 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 63 (5), 915-923
- https://doi.org/10.1007/s00125-020-05108-5
Abstract
Aims/hypothesis Tenascin-C (TN-C) is an extracellular matrix glycoprotein highly expressed in inflammatory and cardiovascular (CV) diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, a condition associated with chronic low-grade inflammation and increased CV disease risk. In this study, we hypothesised that elevated serum TN-C at enrolment in participants with type 2 diabetes would be associated with increased risk of death and major adverse CV events (MACE) during follow-up. Methods We used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE [SUivi Rénal, DIAbète de type 2 et GENEtique] cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. We used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors. Results We monitored 1321 individuals (58% men, mean age 64 ± 11 years) for a median of 89 months. During follow-up, 442 individuals died and 497 had MACE. Multivariate Cox analysis showed that serum TN-C concentrations were associated with an increased risk of death (HR per 1 SD: 1.27 [95% CI 1.17, 1.38]; p < 0.0001) and MACE (HR per 1 SD: 1.23 [95% CI 1.13, 1.34]; p < 0.0001). Using TN-C concentrations on top of traditional risk factors, prediction of the risk of all-cause death (rIDI: 8.2%; p = 0.0006) and MACE (rIDI: 6.7%; p = 0.0014) improved significantly, but modestly. Conclusions/interpretation In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals.Funding Information
- ELSAN clinics (Research grant 2016)
- Groupement pour l’Etude des Maladies Métaboliques et Systémiques
- French Ministry of Health (PHRC-Poitiers 2004; PHRC-IR 2008)
- Association Francaise des Diabetiques (Research grant 2003)
This publication has 40 references indexed in Scilit:
- Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1PLOS ONE, 2013
- Prognostic Value of Serum Tenascin-C Levels on Long-Term Outcome After Acute Myocardial InfarctionJournal of Cardiac Failure, 2012
- Tenascin-C in Cardiovascular Tissue RemodelingCirculation Journal, 2012
- Advances in tenascin-C biologyCellular and Molecular Life Sciences, 2011
- High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patientsAtherosclerosis, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- DAMPening Inflammation by Modulating TLR SignallingMediators of Inflammation, 2010
- Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic SubjectsDiabetes Care, 2008
- Serum Tenascin-C Might Be a Novel Predictor of Left Ventricular Remodeling and Prognosis After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2006
- Tenascins: regulation and putative functions during pathological stressThe Journal of Pathology, 2003